New ETF Book by Larry Connors - Click here to read more
The CUSA ShearTip(TM) is designed to remove tough and tenacious, collagen-rich fibrous tissue that is resistant to fragmentation with traditional ultrasonic tips. This includes fibrous meningiomas and connective tissues.
The CUSA ShearTip(TM) features a unique tip design incorporating Integra's revolutionary ShearWave(TM) Technology. The tip creates shear stresses within fibrous tissue by directing intersecting waves of ultrasonic energy from tapered serrations on the tip end. Unlike traditional ultrasonic tips, the CUSA ShearTip(TM) does not stretch the tissue fibers longitudinally, but allows the ultrasonic waves to break the fibers by cutting through them like a pair of scissors. This increases the removal rate of targeted tissue by up to 50%, enabling the system to address a wider range of tissue types. When used with the unique TissueSelect(TM) function, the ShearTip(TM) provides a wider margin of safety, allowing surgeons to operate more confidently around critical structures.
"The innovative design of the CUSA ShearTip(TM) offers surgeons improved efficacy in fibrous tissue removal, helping to save valuable time in the operating room," said Christopher Thatcher, President of Integra NeuroSciences. "The new tip design will expand the use of the CUSA EXcel(R) platform in neurosurgical applications and beyond."
It is estimated that over 200,000 patients are diagnosed with a brain tumor in the U.S. annually, of which approximately 40,000 have primary brain tumors. The most common primary brain tumors are meningiomas, a type of tumor that develops from the meninges, the membrane that surrounds the brain and spinal cord. Meningiomas are typically asymptomatic in their early stages and often remain undetected for some time. Once the mature tumors are finally detected, they have generally become fibrous and dense, making them difficult to remove with conventional ultrasonic cutting tips.
Integra LifeSciences Holdings Corporation, a world leader in regenerative medicine, is a global medical device company dedicated to improving the quality of life for millions of patients each year. The company's products are used primarily in orthopedics, neurosurgery and general surgery. Headquartered in Plainsboro, New Jersey, Integra has research and manufacturing facilities throughout the world.
This news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include, but are not limited to, statements concerning the future use of the CUSA EXcel(R) and CUSA EXcel(R)+ Ultrasonic Tissue Ablation Systems, CUSA ShearTip(TM), ShearWave(TM) Technology, and TissueSelect(TM). Such forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from predicted or expected results. Among other things, the willingness of physicians to use these products may affect the prospects for their use in clinical procedures. In addition, the economic, competitive, governmental, technological and other factors, identified under the Risk Factors included in Item lA of Integra's Annual Report on Form 10-K for the year ended December 31, 2008, and information contained in subsequent filings with the Securities and Exchange Commission, could affect actual results.
IART-P
This news release was distributed by GlobeNewswire, www.globenewswire.com
SOURCE: Integra LifeSciences Holdings Corp.
CONTACT: Integra LifeSciences Holdings Corporation Gianna Sabella, Director of Corporate Communications (609) 936-2389 gsabella@integra-LS.com
More News:
Market Updates |
Stock Alerts |
All Trading News |
Stock Index
About TradingMarkets | Contact | Advertise | Careers | Link to Us | Site Map | Help | Terms & Conditions | Privacy Policy | Return Policy | Testimonials | Feedback
The Connors Group, Inc. ("Company") is not an investment advisory service, nor a registered investment advisor or broker-dealer and does not purport to tell or suggest which securities or currencies customers should buy or sell for themselves. The analysts and employees or affiliates of Company may hold positions in the stocks, currencies or industries discussed here. You understand and acknowledge that there is a very high degree of risk involved in trading securities and/or currencies. The Company, the authors, the publisher, and all affiliates of Company assume no responsibility or liability for your trading and investment results. Factual statements on the Company's website, or in its publications, are made as of the date stated and are subject to change without notice.
It should not be assumed that the methods, techniques, or indicators presented in these products will be profitable or that they will not result in losses. Past results of any individual trader or trading system published by Company are not indicative of future returns by that trader or system, and are not indicative of future returns which be realized by you. In addition, the indicators, strategies, columns, articles and all other features of Company's products (collectively, the "Information") are provided for informational and educational purposes only and should not be construed as investment advice. Examples presented on Company's website are for educational purposes only. Such set-ups are not solicitations of any order to buy or sell. Accordingly, you should not rely solely on the Information in making any investment. Rather, you should use the Information only as a starting point for doing additional independent research in order to allow you to form your own opinion regarding investments. You should always check with your licensed financial advisor and tax advisor to determine the suitability of any investment.
HYPOTHETICAL OR SIMULATED PERFORMANCE RESULTS HAVE CERTAIN INHERENT LIMITATIONS. UNLIKE AN ACTUAL PERFORMANCE RECORD, SIMULATED RESULTS DO NOT REPRESENT ACTUAL TRADING AND MAY NOT BE IMPACTED BY BROKERAGE AND OTHER SLIPPAGE FEES. ALSO, SINCE THE TRADES HAVE NOT ACTUALLY BEEN EXECUTED, THE RESULTS MAY HAVE UNDER- OR OVER-COMPENSATED FOR THE IMPACT, IF ANY, OF CERTAIN MARKET FACTORS, SUCH AS LACK OF LIQUIDITY. SIMULATED TRADING PROGRAMS IN GENERAL ARE ALSO SUBJECT TO THE FACT THAT THEY ARE DESIGNED WITH THE BENEFIT OF HINDSIGHT. NO REPRESENTATION IS BEING MADE THAT ANY ACCOUNT WILL OR IS LIKELY TO ACHIEVE PROFITS OR LOSSES SIMILAR TO THOSE SHOWN.
The Connors Group, Inc.
10 Exchange Place, Suite 1800
Jersey City, NJ 07302
© Copyright 2009 The Connors Group, Inc.
